MarketCap
Eli Lilly and Company LLY
$ 1 277.31
-0.56%
Facebook
X
Telegram
Eli Lilly and Company P/CF Ratio | LLY
Annual P/CF Ratio Eli Lilly and Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 55.9 | 88.5 | 157 | 39.1 | 30.6 | 28.1 | 39.2 | 48 | 26.2 | 21.9 | 76.2 | 28.5 | 12.8 | 14.6 | 7.89 | 5.25 | 8.78 | 7.14 | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 157 | 5.25 | 38.6 |
P/CF Ratio of other stocks in the Biotechnology industry
| Issuer | P/CF Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Brickell Biotech
BBI
|
-2.62 | - | -5.38 % | $ 6.06 M |  USA |
 |
Applied Therapeutics
APLT
|
-9.8 | - | - | $ 8.42 M | USA |
 |
ESSA Pharma
EPIX
|
-3.24 | - | - | $ 8.86 M |  Canada |
 |
Generation Bio Co.
GBIO
|
-3.39 | - | - | $ 344 M | USA |
 |
Clearside Biomedical
CLSD
|
-5.59 | - | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
-16 | - | - | $ 5.78 B |  Niderland |
 |
RAPT Therapeutics
RAPT
|
-0.568 | - | - | $ 2.36 B | USA |
 |
Exicure
XCUR
|
-3.39 | $ 1.09 | 3.81 % | $ 6.86 M | USA |
 |
Cellectis S.A.
CLLS
|
-8.5 | $ 0.95 | -3.3 % | $ 95.3 M |  France |
 |
AbCellera Biologics
ABCL
|
-7.33 | $ 12.03 | 1.78 % | $ 3.59 B | Canada |
 |
Arrowhead Pharmaceuticals
ARWR
|
34.8 | $ 58.93 | 1.57 % | $ 7.88 B | USA |
 |
BioMarin Pharmaceutical
BMRN
|
14.1 | $ 55.62 | -0.59 % | $ 10.7 B | USA |
 |
Celldex Therapeutics
CLDX
|
-9.67 | $ 29.48 | 0.79 % | $ 1.96 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-0.492 | $ 3.75 | 2.18 % | $ 45.8 M |  Israel |
 |
Jaguar Health
JAGX
|
-0.0404 | $ 2.36 | 15.44 % | $ 5.5 M | USA |
 |
Protalix BioTherapeutics
PLX
|
-14.5 | $ 2.49 | -2.35 % | $ 196 M | Israel |
 |
uniQure N.V.
QURE
|
-3.52 | $ 21.65 | -3.5 % | $ 1.24 B | Niderland |
 |
Stoke Therapeutics
STOK
|
44.1 | $ 25.41 | 1.48 % | $ 1.5 B | USA |
 |
Xencor
XNCR
|
-6.6 | $ 29.2 | 15.95 % | $ 2.17 B | USA |
 |
Annexon
ANNX
|
-4.13 | $ 3.71 | -1.2 % | $ 575 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-0.537 | $ 1.71 | -4.21 % | $ 2.82 M | Israel |
 |
Incyte Corporation
INCY
|
13.8 | $ 113.3 | -2.08 % | $ 22.1 B | USA |
 |
Mesoblast Limited
MESO
|
-31 | $ 12.43 | 1.22 % | $ 15 B |  Australia |
 |
MeiraGTx Holdings plc
MGTX
|
-14 | $ 9.2 | -0.16 % | $ 740 M | USA |
 |
Vertex Pharmaceuticals Incorporated
VRTX
|
34.5 | $ 516.39 | -1.44 % | $ 132 B | USA |
 |
Burford Capital Limited
BUR
|
-95.9 | $ 3.24 | -3.72 % | $ 710 M |  Britain |
 |
Catalyst Biosciences
CBIO
|
989 | $ 12.77 | -0.39 % | $ 1.14 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
8 | $ 25.47 | 1.29 % | $ 1.19 B | USA |
 |
Anika Therapeutics
ANIK
|
19.1 | $ 21.19 | -1.07 % | $ 304 M | USA |
 |
Editas Medicine
EDIT
|
-1.25 | $ 2.4 | 0.05 % | $ 213 M | USA |
 |
Evogene Ltd.
EVGN
|
-0.472 | $ 0.37 | 0.44 % | $ 2.91 M | Israel |
 |
EyePoint Pharmaceuticals
EYPT
|
-0.0048 | $ 0.36 | -10.09 % | $ 26.4 K | USA |
 |
Fortress Biotech
FBIO
|
-1.18 | $ 1.87 | -3.11 % | $ 52.2 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
-13.5 | $ 10.12 | 0.4 % | $ 289 M | USA |
 |
Foghorn Therapeutics
FHTX
|
-4.13 | $ 2.04 | 2.0 % | $ 128 M | USA |
 |
Dr. Reddy's Laboratories Limited
RDY
|
0.264 | $ 13.76 | 4.13 % | $ 11.5 B |  India |
 |
Arcturus Therapeutics Holdings
ARCT
|
-2.92 | $ 9.91 | 0.71 % | $ 271 M | Israel |
 |
Sanofi
SNY
|
5.51 | $ 41.77 | 0.41 % | $ 51 B | France |
 |
Arcutis Biotherapeutics
ARQT
|
-612 | $ 31.74 | 1.73 % | $ 4.04 B | USA |
 |
Geron Corporation
GERN
|
-9.55 | $ 1.15 | 2.23 % | $ 767 M | USA |
 |
Gossamer Bio
GOSS
|
-0.627 | $ 9.2 | -4.27 % | $ 2.1 B | USA |
 |
Titan Pharmaceuticals
TTNP
|
-0.738 | - | -3.76 % | $ 3.47 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-0.57 | - | 3.16 % | $ 1.9 M | USA |
 |
ALX Oncology Holdings
ALXO
|
-1.36 | $ 1.14 | -2.56 % | $ 61.2 M | USA |
 |
Heron Therapeutics
HRTX
|
-7.19 | $ 0.3 | -0.46 % | $ 50 M | USA |
 |
Achieve Life Sciences
ACHV
|
-2.56 | $ 6.55 | 0.85 % | $ 286 M | USA |
 |
TCR2 Therapeutics
TCRR
|
-0.571 | - | - | $ 58.1 M | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
13.7 | $ 17.02 | 0.98 % | $ 2.29 B | Canada |
 |
iBio
IBIO
|
-6.1 | $ 0.71 | -1.28 % | $ 73.9 M | USA |
 |
ImmuCell Corporation
ICCC
|
23.4 | $ 10.21 | -0.37 % | $ 92.2 M | USA |